Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your genes could guide safer drug doses

NCT ID NCT05508763

Prevention Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether using a genetic test to guide medication dosing can reduce serious side effects. Researchers will compare 2000 patients who receive genetically tailored dosing against those receiving standard care. Participants will report any side effects over one year. The goal is to see if this personalized approach makes common drugs safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A genetic test that checks 14 genes involved in drug processing, used to guide medication dosing
What this could lead to
If it works, this could make common medications safer by matching doses to each person's genetic makeup, reducing severe side effects.
What could go wrong
The trial is early and large, but genetic testing may not always predict side effects, and implementing it in routine care could be challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients of 18 years of age or older that participate in medication verification in the LUMC are eligible to participate.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of informed consent (IC) prior to any study specific procedures. * Be aged ≥18 * A venapunction as part of routine treatment * Receive a medication verification interview * Be able and willing to be followed-up for at least one year Exclusion Criteria: * Pregnancy or lactating * Previous participation in the PREPARE trial (NCT03093818, NL60069.058.16)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse drug reaction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse drug reaction

Contacts and locations

Locations

  • Leiden University Medical Center

    Leiden, South Holland, 2333ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.